πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

149 results for β€œrecombinant” Clear

  1. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 2 small molecule active

    1 trial

  2. BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1)

    BioMarin Pharmaceutical Australia Pty Ltd

    Jansky-Bielschowsky Disease

    phase 2 mab completed

    1 trial

  3. Gardasil 9 suspension for injection. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)

    Astra Zeneca AB

    Recipients of allogeneic stem cell transplantation

    phase 2 small molecule active

    1 trial

  4. Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 2 mab completed

    1 trial

  5. Multivalent recombinant OspA Lyme Borreliosis Vaccine

    Takeda

    Prophylaxis of Lyme Borreliosis

    phase 2 mab completed

    1 trial

  6. Open-label, safety, tolerability and proof of concept study to evaluate the use of ANXV (recombinant human Annexin A5 protein) in the treatment of patients with either Diabetic Retinopathy or recent onset Retinal Vein Occlusion

    Lacuna Pharma Pty Ltd

    Diabetic Retinopathy, Retinal Vein Occlusion

    phase 2 other active

    1 trial

  7. Part1:Recombinant two-component COVID-19 vaccine (CHO cell)

    Jian Li

    COVID-19

    phase 2 mab completed

    1 trial

  8. RECOMBINANT ADAMTS13 (rADAMTS13), -, RITUXIMAB

    Takeda

    Immune-mediated thrombotic thrombocytopenic purpura (iTTP)

    phase 2 small molecule active

    1 trial

  9. Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Psoriasis

    phase 2 small molecule active

    1 trial

  10. Recombinant Anti-IL-1Ξ² Humanized Monoclonal Antibody Injection 100 mg

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Gout Arthritis

    phase 2 small molecule active

    1 trial

  11. Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Dermatitis, Atopic

    phase 2 small molecule active

    1 trial

  12. Recombinant COVID-19 Vaccine (CHO cell)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19 Pneumonia

    phase 2 mab active

    1 trial

  13. Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19 Pneumonia

    phase 2 mab active

    1 trial

  14. Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 2 mab active

    1 trial

  15. Recombinant Human Endostatin Injection

    The First People's Hospital of Lianyungang

    Locally Advanced Squamous Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. Recombinant Human Erythropoiesis Injection (CHO cell)

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic Renal Failure With Hemodialysis

    phase 2 small molecule active

    1 trial

  17. Recombinant Interferon Alpha

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Essential Thrombocytopenia

    phase 2 small molecule active

    2 trials

  18. Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)

    BRIGHT MINDS BIOSCIENCES INC.

    Human Papilloma Virus Infection

    phase 2 mab completed

    1 trial

  19. Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio) low adjuvant dose

    CanSino Biologics

    Poliomyelitis

    phase 2 mab active

    1 trial

  20. Recombinant anti-PD-1 humanized monoclonal antibody injection

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Sarcoma, Soft Tissue

    phase 2 small molecule active

    1 trial

  21. Recombinant human Arylsulfatase A (rhASA)

    Takeda

    Late Infantile Metachromatic Leukodystrophy

    phase 2 mab completed

    1 trial

  22. Recombinant human arylsulfatase A

    Takeda

    Metachromatic Leukodystrophy (MLD)

    phase 2 mab completed

    1 trial

  23. Recombinant human arylsulfatase A

    Shire

    Metachromatic Leukodystrophy (MLD)

    phase 2 mab completed

    1 trial

  24. Recombinant human endostatin

    The First People's Hospital of Lianyungang

    Stage III Non-small-Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources